Lv6
2800 积分 2021-12-27 加入
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
1个月前
已完结
[Expert consensus on the diagnosis and treatment of esophageal and gastric variceal rupture bleeding in cirrhotic portal hypertension (2024 edition)]
1个月前
已完结
What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
3个月前
已关闭
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
3个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
4个月前
已完结
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
4个月前
已完结
Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management
4个月前
已完结
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
4个月前
已完结
Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events
4个月前
已关闭
Precision models in hepatocellular carcinoma
4个月前
已完结
皖公网安备34019202002308
